In HFrEF, therapy in patients with frailty often not optimized despite high risk

In patients with HF with reduced ejection fraction, those with frailty had elevated risk for poor outcomes but less likelihood of being on optimal guideline-directed medical therapy, according to new data from the GUIDE-IT trial.
As Healio previously reported, in the main results of GUIDE-IT, a strategy guided by N-terminal pro-B-type natriuretic peptide levels did not benefit patients with HFrEF more than the usual care. For the present post hoc analysis published in JACC: Heart Failure, researchers stratified the cohort into three groups based on frailty index score and compared frailty

In patients with HF with reduced ejection fraction, those with frailty had elevated risk for poor outcomes but less likelihood of being on optimal guideline-directed medical therapy, according to new data from the GUIDE-IT trial.
As Healio previously reported, in the main results of GUIDE-IT, a strategy guided by N-terminal pro-B-type natriuretic peptide levels did not benefit patients with HFrEF more than the usual care. For the present post hoc analysis published in JACC: Heart Failure, researchers stratified the cohort into three groups based on frailty index score and compared frailty